CVS proves pharmacists impact diabetes outcomes.
WOONSOCKET, R.I. —Serving as yet one more indicator of the vital role that pharmacists play in the U.S. healthcare system is a program implemented by CVS Caremark and Polk County, Fla., that clearly illustrates how clinical pharmacist interventions can improve diabetes outcomes for patients.
As explained in a case study published in a recent issue of the American Journal of Health-Systems Pharmacists, the program has resulted in improvements in key clinical measurements for enrolled members, such as decreased glycosylated hemoglobin and lowered blood pressure levels. A reduction in emergency room visits and in-patient hospital admissions also were recorded—improvements that also should be noted, given the current strain on emergency rooms.
To understand how the program has helped those with diabetes manage their health, let’s back up to February 2005, which is when Polk County, a self-insured government employer client, implemented the Contract for Care program. Polk County is one of the largest population concentrations in the Southeast, and the fourth-largest county in Florida at 2,010 total sq. miles.
Enrolled Polk County employees agree to work with a CVS Caremark clinical pharmacist, located on-site at the county’s employee health clinic, to develop individualized care plans and coordinate regular follow-up. Enrolled members receive copay waivers on disease-related medications—generic and branded—as well as related supplies and nonprescription products.
Sound a bit familiar? Think: The Asheville Project. The Asheville Project began in 1996 as an effort by the City of Asheville, N.C., a self-insured employer. Patients were teamed with community pharmacists, who made sure they were using their medications correctly, and soon began experiencing improved outcomes.
At the end of the first year of Polk County’s Contract for Care program, 477 members were enrolled and were included in the analysis. The study’s primary outcome was the change in clinical values for glycosylated hemoglobin, a critical measurement of blood sugar levels. After one year, the reduction in glycosylated hemoglobin values was especially high among members in the critical risk group, with nearly 78% of these members achieving a significant reduction. Mean systolic blood pressure decreased six points, and mean diastolic blood pressure decreased four points. Medical claims data revealed a 30% drop in all cause-hospitalizations and a 24% drop in ER visits for enrolled members.
Clearly, the benefits of the program are twofold; enrollees are improving their health, and it underscores the importance of pharmacist intervention in improving patient health outcomes.
In separate news, CVS Caremark is expanding its research efforts to develop ways to improve medication adherence.
Through the Behavior Change Research Partnership, CVS Caremark is working with academic leaders from Carnegie Mellon University, Dartmouth College’s Tuck School of Business and the University of Pennsylvania’s Medical School and Wharton School of Business.
The partnership will study reasons why people who go to the doctor often choose not to fill their initial prescriptions or prematurely stop taking those medications during treatment and recovery. It also will examine why consumers may choose to buy more expensive brand medications when they have access to generic drugs that may provide identical or similar health outcomes.
Late-stage clinical trial of Avastin fails to meet expectations, Genentech says
SOUTH SAN FRANCISCO, Calif. A late-stage clinical trial of a Genentech drug for men with late-stage prostate cancer has failed, the biotech company announced Friday.
Genentech, part of Swiss drug maker Roche, announced that a phase 3 trial of Avastin (bevacizumab) combined with prednisone and the chemotherapy drug docetaxel did not extend the amount of time that patients survived, compared with chemotherapy and prednisone alone.
The drug already has approval from the Food and Drug Administration for treating tumors and cancers of the lungs, colon, rectum, breasts, kidneys and brain.
Abbott’s submits supplemental approval application for Lupron Depot to FDA
ABBOTT PARK, Ill. Abbott is hoping that the Food and Drug Administration will approve one of its drugs as a treatment for advanced prostate cancer.
The Chicago-based drug maker announced Thursday that the FDA accepted its supplemental approval application for Lupron Depot (leuprolide acetate) in the 45-mg strength. The drug, an injectable, works by suppressing production of testosterone for six months. It is currently available in 7.5-mg, 22.5-mg and 30-mg formulations that work for one, three and four months.
“For many patients with advanced prostate cancer, Lupron Depot is an important treatment option because it can help manage the symptoms of their disease,” Abbott VP global pharmaceutical development Eugene Sun said in a statement. “Abbott is seeking approval for a new six-month formulation to provide greater convenience and dosing flexibility to physicians and patients who could benefit form this medication.”